Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
227.5 USD | +0.90% | -0.88% | -11.98% |
01:00pm | US FDA advisers to review Eli Lilly Alzheimer's drug | RE |
09:44am | Biogen, Eisai Say Alzheimer's Maintenance Treatment Application Accepted by US FDA | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's enterprise value to sales, at 3.76 times its current sales, is high.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.98% | 32.82B | B- | ||
+0.82% | 91.94B | A- | ||
-3.16% | 38.74B | A- | ||
+64.83% | 26.66B | A | ||
-12.60% | 15.32B | C | ||
-5.76% | 13.3B | B- | ||
-11.38% | 11.65B | D+ | ||
+156.85% | 10.37B | D | ||
-49.84% | 10.12B | B | ||
+2.32% | 9.06B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIIB Stock
- Ratings Biogen Inc.